The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids

To evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months.

[1]  R. Eastell,et al.  Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. , 2020, The Journal of clinical endocrinology and metabolism.

[2]  B. Langdahl,et al.  Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  F. Wolfe,et al.  Medications associated with fracture risk in patients with rheumatoid arthritis , 2019, Annals of the rheumatic diseases.

[4]  Ji-Min Kim,et al.  Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria , 2018, Journal of clinical medicine.

[5]  Jacques P. Brown,et al.  Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  P. Geusens,et al.  Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. , 2018, The lancet. Diabetes & endocrinology.

[7]  I. Reid,et al.  Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates , 2018, Calcified Tissue International.

[8]  Jacques P. Brown,et al.  Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Haifeng Guo,et al.  Bone fracture risk in patients with rheumatoid arthritis , 2017, Medicine.

[10]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2017 .

[11]  D. Aeberli,et al.  Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures , 2017, Osteoporosis International.

[12]  Hang Lee,et al.  Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). , 2017, Bone.

[13]  Y. Fujiwara,et al.  Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. , 2016, American journal of physiology. Endocrinology and metabolism.

[14]  K. Saag,et al.  Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis , 2016, Osteoporosis International.

[15]  N. Freemantle,et al.  Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.

[16]  J. S. San Martin,et al.  Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. , 2011, The Journal of clinical endocrinology and metabolism.

[17]  R. Rizzoli,et al.  Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  Stanley B. Cohen,et al.  Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates , 2009, Annals of the rheumatic diseases.

[19]  B. Bresnihan,et al.  Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade , 2010, Rheumatology International.

[20]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[21]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[22]  Sundeep Khosla,et al.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.

[23]  R. Kitazawa,et al.  Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels , 2008, Journal of cellular biochemistry.

[24]  Steven W. Martin,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  A. Bertolotto,et al.  Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  Stanley B. Cohen,et al.  Oral glucocorticoid use is associated with an increased risk of fracture , 2004, Osteoporosis International.

[27]  H. Frost.  Bone's mechanostat: a 2003 update. , 2003, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[28]  W. Kratzer,et al.  Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease , 2003, European journal of gastroenterology & hepatology.

[29]  P. Tak,et al.  Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis , 2002, Annals of the rheumatic diseases.

[30]  A. Algra,et al.  Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. , 2001, Rheumatology.

[31]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[32]  D. Lacey,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .